| 2.24 0.26 (13.13%) | 10-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.82  |
1-year : | 4.85 |
| Resists | First : | 3.27 |
Second : | 4.15 |
| Pivot price | 2.42 |
|||
| Supports | First : | 1.83 | Second : | 1.52 |
| MAs | MA(5) : | 2.11 |
MA(20) : | 2.68 |
| MA(100) : | 4.79 |
MA(250) : | 13.77 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 12.1 |
D(3) : | 8.3 |
| RSI | RSI(14): 32.6 |
|||
| 52-week | High : | 71.5 | Low : | 1.83 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ERNA ] has closed above bottom band by 37.1%. Bollinger Bands are 48.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.26 - 2.28 | 2.28 - 2.29 |
| Low: | 1.86 - 1.88 | 1.88 - 1.89 |
| Close: | 2.22 - 2.24 | 2.24 - 2.26 |
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.
Thu, 15 Oct 2026
Ernexa Therapeutics posts investor presentation under Regulation FD, available on investor site - TradingView
Mon, 12 Oct 2026
A cell-based cancer therapy is moving toward testing in people. Ernexa executives will discuss it Oct. 15. - Stock Titan
Tue, 06 Oct 2026
In animal tests, cell therapy plus immune treatment fully controlled ovarian tumors in most animals. - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 29.5 (%) |
| Held by Institutions | 2.1 (%) |
| Shares Short | 20 (K) |
| Shares Short P.Month | 20 (K) |
| EPS | -13.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.73 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -105.6 % |
| Return on Equity (ttm) | -320.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -7.18 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.17 |
| PEG Ratio | 0 |
| Price to Book value | 0.82 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|